May 21, 2026
Laurus Labs included in Dow Jones Best-in-Class indices
The company listed its inclusion in the Dow Jones Best-in-Class indices in its regulatory disclosures.
#Sustainability #Recognition
View post
An India-based pharmaceutical development and manufacturing company.
lauruslabs.comLegal name
Laurus Labs Limited
Founded
2005
Headquarters
Hyderabad, Telangana, IndiaIndustry
Pharmaceutical development and manufacturing
Revenue (FY26)
₹6,813 croreEBITDA (FY26)
₹1,826 crore
EBITDA margin (FY26)
26.8%
Employees
8,126
Manufacturing sites
15
CEO
Dr. Satyanarayana Chava
Laurus Labs is a research-driven pharmaceutical manufacturing organization founded in 2005. It develops and manufactures active pharmaceutical ingredients, intermediates and finished dosage forms for global pharmaceutical customers.
The company identifies anti-retroviral, oncology, cardiovascular and gastro therapeutics among the API areas where it has built capabilities. Its group also describes CDMO, biologics, pharmaceutical ingredients and finished-dosage activities.
For FY26, Laurus reported revenue from operations of ₹6,813 crore and EBITDA of ₹1,826 crore. The company reports 15 manufacturing sites, 8,126 employees and six R&D sites in its FY26 annual-report highlights.
Executive Director and Chief Executive Officer
Executive Director and Chief Financial Officer
Executive Director, Quality
Executive Director, CDMO Small Molecules

Interview experience
No numeric score verified
Interview difficulty
No numeric score verified
Interview process length
Varies by role
Browse question banks by role, round and company, with answers and examples.
May 21, 2026
Laurus Labs included in Dow Jones Best-in-Class indices
The company listed its inclusion in the Dow Jones Best-in-Class indices in its regulatory disclosures.
#Sustainability #Recognition
View postMay 13, 2026
Laurus publishes IEPF share-transfer notice
The company published a notice concerning transfer of shares to the Investor Education and Protection Fund Authority.
#Investor #Disclosure
View postMay 8, 2026
Laurus publishes second-interim-dividend TDS notice
The company published instructions for TDS documents related to its second interim FY26 dividend.
#Dividend #Investor
View postMay 2, 2026
Laurus publishes FY26 financial-results notice
The company published its newspaper notice for the quarter and year ended March 31, 2026.
#Results #Investor
View postApril 30, 2026
Laurus Labs announces full-year FY26 results
The company reported FY26 revenue of ₹6,813 crore and EBITDA of ₹1,826 crore.
#Results #Pharma
View postIts corporate office is in Hyderabad, Telangana, India.
Last updated: